###begin article-title 0
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 500 506 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 82 87 <span type="species:ncbi:9606">human</span>
Germline genetic variation is associated with the differential expression of many human genes. The phenotypic effects of this type of variation may be important when considering susceptibility to common genetic diseases. Three regions at 8q24 have recently been identified to independently confer risk of prostate cancer. Variation at 8q24 has also recently been associated with risk of breast and colorectal cancer. However, none of the risk variants map at or relatively close to known genes, with c-MYC mapping a few hundred kilobases distally.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 780 784 780 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6</italic>
###xml 886 891 886 891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC</italic>
This study identifies cis-regulators of germline c-MYC expression in immortalized lymphocytes of HapMap individuals. Quantitative analysis of c-MYC expression in normal prostate tissues suggests an association between overexpression and variants in Region 1 of prostate cancer risk. Somatic c-MYC overexpression correlates with prostate cancer progression and more aggressive tumor forms, which was also a pathological variable associated with Region 1. Expression profiling analysis and modeling of transcriptional regulatory networks predicts a functional association between MYC and the prostate tumor suppressor KLF6. Analysis of MYC/Myc-driven cell transformation and tumorigenesis substantiates a model in which MYC overexpression promotes transformation by down-regulating KLF6. In this model, a feedback loop through E-cadherin down-regulation causes further transactivation of c-MYC.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
This study proposes that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline c-MYC expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor KLF6 gene.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 476 477 476 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 584 585 584 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 586 587 586 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 695 696 695 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 724 730 724 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 980 981 980 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 8 13 <span type="species:ncbi:9606">human</span>
Risk of human cancer associated with genetic variation at chromosome 8q24 was first described for prostate cancer in individuals with European ancestry and in African Americans (Risk Region 1) [1,2]. This association was stronger for more aggressive tumor forms [2-4] and for earlier age at diagnosis in African Americans [1,5]. Differences in allele prevalences could account for the higher incidence of prostate cancer in particular populations such as African-Americans [1,2,5]. Subsequently, 8q24 has been associated with risk of prostate cancer by two extra independent regions [6-8] and in risk of breast and colorectal cancer by variation partially overlapping with prostate cancer risk [9-13]. In particular, Haiman et al.[12] first noted the existence of common risk variants for breast and colorectal cancer at 8q24. These observations suggest that multiple cancer genes may exist at 8q24 or, alternatively, that risk variants converge on a common biological mechanism [7].
###end p 9
###begin p 10
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 503 509 503 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 607 613 607 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
In these studies risk variants did not map to known genes, with few ESTs identified in relatively close proximity. A proposed mechanism includes differences in genomic structure that would make the 8q24 region more prone to subsequent somatic amplification [14]. The c-MYC gene is of particular interest in this region because its ectopic expression has been shown to induce prostatic neoplasia [15-17]. Here, we analyze genetic and genomic data to provide evidence of 8q24 cis-regulator(s) of germline c-MYC transcription. In addition, genomic data modeling predicts a molecular mechanism linking germline c-MYC overexpression and prostate tumorigenesis.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
Genetic association scan for germline expression differences
###end title 12
###begin p 13
###xml 60 66 60 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 295 297 295 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 818 819 818 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Scanning associations between genetic variation at 8q24 and c-MYC gene expression levels in immortalized lymphocytes of HapMap CEU (Utah residents with ancestry from Northern and WesternEurope) and YRI (Yoruba in Ibadan Nigeria) individuals showed the existence of clusters of SNPs with nominal P values < 0.05 (Fig. 1). To assess clustering significance, we examined the proportion of significant SNPs in genomic windows 2- or 4-fold the average size of linkage disequilibrium blocks in CEUs or YRIs, respectively (~42 kb corresponding to ~66 SNPs in CEUs and ~36 kb corresponding to ~61 SNPs in YRIs). Twenty thousand permutations were performed to evaluate the significance of the observed clustering. One genomic region in CEUs and three regions in YRIs were identified with high density of significant SNPs (Fig. 1).
###end p 13
###begin p 14
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 289 291 289 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 633 639 633 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D'/LOD</italic>
Genetic association scan for germline c-MYC differential expression in CEUs and YRIs. (A) Top panel shows results for individual SNPs and bottom panel shows results for significant SNP density in genomic windows of ~42 kb/~66 SNPs in CEUs. The red horizontal dashed line marks the nominal P value of 0.05. Variants associated with risk of breast [9], colorectal [10-13] or prostate [1-8, 24] cancer are marked with dashed lines as indicated in the inset. (B) Top panel shows results for individual SNPs and bottom panel shows results for significant SNP density in genomic windows of ~36 kb/~61 SNPs in YRIs. Linkage disequilibrium (D'/LOD) plots are shown at the bottom for YRIs. Region 1 of prostate cancer risk is shown.
###end p 14
###begin p 15
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 286 291 286 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC</italic>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
Variation at the c-MYC locus was observed with a trend in CEUs, which might suggest the existence of cis-regulators in the gene structural elements (blue bar in Fig. 1A). Two variants in this region (rs4645943 C and rs16902364 A) are associated with germline differential expression of c-MYC. The allele frequencies of these SNPs were reported to differ between prostate cancer cases and controls in different populations (i.e. 87.7% (cases) and 77.7% (controls) in Hawaiians; 96.3% (cases) and 95.1% (controls) in CEUs for rs4645943 C) [7]. This observation warrants further genetic analysis of the region with regard to prostate cancer risk.
###end p 15
###begin p 16
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 276 278 276 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 408 410 408 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 459 461 459 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 571 573 571 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 667 673 667 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
The scan revealed a possible association between variants in Region 1 of prostate cancer risk and differential germline expression of c-MYC (Fig. 1B). Several significant SNPs within this region were identified: the most significant were rs7387447, rs10808558 and rs16902176 (P values < 0.01). The rs10808558 A allele showed an association with c-MYC overexpression in YRIs (expression difference of 0.23 log2 units, 95% confidence interval (CI) 0.06 - 0.41; P = 0.007) and this SNP is in low linkage disequilibrium (LD) with the prostate cancer risk variant rs1447295 (r2 = 0.19). Overall, the scan analysis suggests the existence of 8q24 cis-regulators of germline c-MYC transcription in lymphocytes, partially overlapping with Region 1 of prostate cancer risk.
###end p 16
###begin title 17
Expression differences in normal prostate tissues
###end title 17
###begin p 18
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 723 726 723 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">18S</italic>
###xml 728 734 728 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALAS1 </italic>
###xml 738 741 738 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 766 772 766 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 884 886 884 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1076 1082 1076 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
Given the possible association of Region 1 variants with germline c-MYC overexpression in immortalized lymphocytes of HapMap individuals, we next examined expression differences in normal prostate tissues. For this analysis we used 54 previously characterized normal prostate tissue samples [18,19] and a real-time qRT-PCR protocol developed for prostate samples [20-22]. Genotyping the prostate cancer-associated rs1447295 variant in these samples identified six heterozygotes harboring the risk allele A (CA genotypes). No significant age differences were found between donors harboring the two different genotypes (CA versus CC; no AA homozygotes were identified). Quantitative RT-PCR study using three gene references (18S, ALAS1 and TBP) identified significant c-MYC overexpression in samples harboring the risk allele relative to CC homozygotes (n = 26) (Wilcoxon rank sum test P = 0.004) (Fig. 2A). In addition, no evidence of allele-specific amplification in tumors arising in CA individuals was observed (not shown). These results suggest the involvement of germline c-MYC overexpression in prostate cancer susceptibility.
###end p 18
###begin p 19
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 180 182 180 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R </italic>
###xml 184 185 184 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 185 191 185 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>c</italic>-<italic>MYC </italic></sub>
###xml 194 195 194 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 195 199 195 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 195 199 195 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>TBP </italic></sub>
###xml 201 202 201 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALAS</italic>
###xml 202 207 202 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ALAS</italic>1</sub>
###xml 215 216 215 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gene i</italic>
###xml 216 222 216 222 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>gene i</italic></sub>
###xml 224 226 224 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 226 233 226 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gene i </italic>
###xml 226 233 226 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>gene i </italic></sub>
###xml 235 237 235 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 237 241 237 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">18 <italic>S</italic></sub>
###xml 247 253 247 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 358 364 358 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
Analysis of c-MYC expression in normal and prostate cancer tissues. (A) Relative expression differences of c-MYC calculated using three gene references with the following formula: R = Fc-MYC - (FTBP - FALAS1) where Fgene i= Ctgene i - Ct18 S. (B) c-MYC expression in prostate cancer progression. Mean expression values are marked by a red solid rhombus. (C) c-MYC expression association study with Gleason scores.
###end p 19
###begin title 20
Germline copy number variants
###end title 20
###begin p 21
###xml 112 118 112 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 645 651 645 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 735 741 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 787 793 787 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 835 841 835 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 631 634 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 821 824 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
As a possible mechanism explaining germline overexpression, we next examined copy number variants (CNVs) at the c-MYC locus in CEUs and YRIs, and in 322 unrelated individuals from the Spanish general population using a multiplex ligation-dependent probe amplification (MLPA) assay. This assay identified genomic gains at the c-MYC locus at a relatively low frequency in the Spanish general population (< 1%; 2/322) (Additional file 1). However, analysis of rs1447295 genotypes in these individuals did not reveal association with the risk allele and, importantly, none of the CEUs or YRIs showed CNVs with this assay. Therefore, a CNV including c-MYC does not seem to be a major contributor to the risk of prostate cancer and germline c-MYC overexpression associated with Region 1. Wong et al.[23] previously described a CNV including c-MYC but only with genomic losses. This observation corroborates the structural complexity of 8q24 and opens the possibility that different genomic configurations are associated with risk alleles in Region 1 or other 8q24 regions.
###end p 21
###begin title 22
Gene expression analysis in prostate tumors
###end title 22
###begin p 23
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Since Region 1 variants were associated with earlier age at diagnosis and high Gleason scores or aggressive tumor forms [1-8,24], we examined the expression level of 8q24 genes in primary prostate tumors and their association with clinical and pathological variables. For these analyses, we used a publicly available expression data set containing different prostate cellular populations isolated using laser-capture microdissection [25].
###end p 23
###begin p 24
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 241 243 241 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 247 249 247 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3</sup>
###xml 260 266 260 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 368 375 368 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAM84B </italic>
###xml 444 446 444 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 458 460 458 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 549 556 549 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FAM84B </italic>
###xml 656 662 656 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 689 691 689 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 731 737 731 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 815 821 815 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 822 824 822 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 838 844 838 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 916 922 916 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
Comparison of normal versus neoplastic samples showed differential expression of c-MYC (Fig. 2B). Specifically, overexpression appears in the more advanced stages of tumorigenesis such as carcinomas and hormone-refractory metastases (t-test P < 10-3). Tomlins et al.[25] previously noted the identification of c-MYC in an "overexpressed in progression" signature. The FAM84B gene at 8q24 also shows overexpression but mainly at earlier stages (P = 0.043 and P = 0.002 for intraepithelial neoplasia and carcinomas, respectively), which suggests that FAM84B could also be a target of 8q24 somatic amplification. Analysis of Gleason scores showed a trend for c-MYC overexpression (ANOVA test P = 0.056) (Fig. 2C). Association between c-MYC overexpression and high-grade prostate tumors was previously noted by Buttyan et al.[26] and Fleming et al.[27]. These observations point to a causal relationship between somatic c-MYC overexpression and the more aggressive forms of prostate tumors.
###end p 24
###begin title 25
Expression profiles and modeling of transcriptional regulatory networks
###end title 25
###begin p 26
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 495 501 495 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 535 564 535 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Kruppel-like factor 6 (KLF6) </italic>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 611 617 611 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 707 709 707 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 713 716 713 716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-13</sup>
###xml 759 761 759 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 765 768 765 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-15</sup>
###xml 809 815 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Transcriptional targets of MYC include many genes that were identified as conferring risk of prostate cancer and/or being somatically mutated in prostate tumors [28,29]. We sought to identify which of these genes, particularly those conferring risk of prostate cancer, could be functionally associated with c-MYC by examining the similarity between expression profiles using a data set containing 50 normal tissues and 52 prostate tumors [30]. This analysis revealed strong correlations between c-MYC and the prostate tumor suppressor Kruppel-like factor 6 (KLF6) gene (Fig. 3A). Correlations were positive for c-MYC microarray probes 1973_s_at and 37724_at (Pearson's correlation coefficient (PCC) = 0.65; P < 10-13) and negative for 1827_s_at (PCC = -0.71; P < 10-15). Extensive alternative splicing of the c-MYC mRNA could account for this difference [31].
###end p 26
###begin p 27
###xml 106 112 106 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
Expression profiling and modeling of transcriptional regulatory networks. (A) Transcriptional profiles of c-MYC and KLF6 in prostate tissues [30] using U95A Affymetrix probes shown in the inset. (B) Integrated transcriptional regulatory networks of MYC and KLF6. Gene function assignment based on GO term annotations and known MYC transcription targets are shown as indicated in the inset.
###end p 27
###begin p 28
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 535 537 535 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 880 882 880 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 894 900 894 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 904 909 904 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 946 951 946 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1083 1087 1083 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6</italic>
###xml 1149 1152 1149 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOS</italic>
###xml 1154 1159 1154 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JUNB </italic>
###xml 1163 1168 1163 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ZFP36</italic>
###xml 1175 1181 1175 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPFIA3</italic>
###xml 1250 1257 1250 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPFIBP2</italic>
###xml 1265 1267 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1317 1321 1317 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6</italic>
###xml 1323 1329 1323 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
To determine the molecular consequence of the predicted MYC-KLF6 functional association, we generated models of transcriptional regulatory networks in prostate tissues. Using the ARACNe algorithm [32] and the 102 hybridizations of Singh et al.[30], we identified 88 and 111 putative transcriptional targets of MYC and KLF6 in this cell type, respectively (Fig. 3B). The intersection of these two sets contains 25 genes, which is a much larger number of genes than randomly expected using simulations of equivalent gene sets (empirical P < 0.001). Importantly, 16 of these genes contain MYC binding sites at their promoters based on TRANSFAC (eukaryotes transcription factors database) matrices [33]. In addition, many known MYC targets [29] were also identified: 22 out of 88 (25%) and 23 out of 111 (20%) of the MYC and KLF6 predicted transcriptional targets, respectively (Fig. 3B). Notably, c-MYC and KLF6 were also directly connected and the KLF6 promoter contains three predicted binding sites for MYC (not shown). A 5-gene recurrence predictor of prostate cancer [34] contains KLF6, three common ARACNe-based predictions between MYC and KLF6 (FOS, JUNB and ZFP36), and PPFIA3, which is functionally related to another predicted target of KLF6 (PPFIBP2) (Fig. 3B). These observations further support the role of KLF6, c-MYC and the ARACNe-based predictions in prostate tumorigenesis.
###end p 28
###begin p 29
###xml 56 62 56 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 246 248 246 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Comparison of ARACNe-based predictions with the Tomlins et al. data set [25] identified 13 of the 88 predicted MYC transcriptional targets differentially expressed between normal prostate tissues and androgen-independent metastases (FDR-adjusted P values < 0.05). In addition, 20 of the predicted targets were found to be differentially expressed between normal prostate tissues and adenocarcinomas. Notably, ~46-40% of these genes (6/13 and 8/20) were also predicted to be direct transcriptional targets of KLF6 by the ARACNe algorithm, which endorses the putative functional association between MYC and KLF6.
###end p 29
###begin title 30
Analysis of MYC/Myc-driven cellular transformation and tumorigenesis
###end title 30
###begin p 31
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 576 579 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#967;</italic>
###xml 579 580 577 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 586 588 584 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 746 751 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 820 821 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 827 829 825 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 840 842 838 840 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-3</sup>
###xml 850 852 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 198 203 <span type="species:ncbi:9606">human</span>
###xml 238 242 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 409 414 <span type="species:ncbi:9606">human</span>
To evaluate the functional significance of the predicted shared MYC/KLF6 transcriptional targets, we examined expression data derived from a model of MYC-driven cellular transformation of quiescent human mammary epithelial cells and from MMTV-Myc-driven mammary tumors in mice [35,36]. Of the 25 predicted common targets, 16 (64%) were found to be differentially expressed in cell transformation of quiescent human mammary epithelial cells (Fig. 4A). This proportion is ~2-fold higher than expected by chance taking into account all genes examined in the microarray platform (chi2-test P = 0.004), which substantiates the identification of true MYC targets. Moreover, 11 of the 16 genes contain MYC binding sites at their promoters. Importantly, KLF6 was also identified and showed strong down-regulation in this model (t-test P values < 10-3) (Fig. 4A).
###end p 31
###begin p 32
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 373 375 373 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 164 169 <span type="species:ncbi:9606">human</span>
###xml 232 236 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 258 262 <span type="species:ncbi:10090">mice</span>
Expression analysis of predicted MYC/KLF6 transcriptional targets in MYC/Myc-driven cell transformation and tumorigenesis. (A) Results of the analysis of quiescent human mammary epithelial cells [36]. (B) Results of the analysis of MMTV-Myc-driven tumors in mice [35]. Genes (red, up-regulated; green, down-regulated), corresponding microarray probes and two-tailed t-test P values are shown.
###end p 32
###begin p 33
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Myc</italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TGIF </italic>
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 482 484 482 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 535 540 535 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Klf6 </italic>
###xml 557 559 557 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 574 576 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 605 615 605 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6/Klf6 </italic>
###xml 722 728 722 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 881 886 881 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 12 16 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
###xml 108 113 <span type="species:ncbi:9606">human</span>
###xml 227 232 <span type="species:ncbi:9606">human</span>
###xml 356 361 <span type="species:ncbi:9606">human</span>
###xml 469 473 <span type="species:ncbi:10090">mice</span>
Analysis of MMTV-Myc-driven mammary tumors in mice showed consistent results with the analysis of quiescent human mammary epithelial cells. Twelve differentially expressed genes were detected, eight of which coincided with the human genes mentioned above (Fig. 4B). Genes that did not overlap between the two studies showed similar trends, for example the human TGIF showed a trend for down-regulation (P = 0.067) while it was identified as significant in the study of mice tumors (P = 0.007). Importantly, this analysis also revealed Klf6 down-regulation (P = 0.003) (Fig. 4B). Overall, the discovery of KLF6/Klf6 down-regulation in two different models of MYC/Myc-driven cell transformation supports the hypothesis that c-MYC germline overexpression could act as a risk factor for prostate cancer by converging on a molecular mechanism such as the functional inactivation of the KLF6 gene or gene product.
###end p 33
###begin p 34
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 209 215 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN1A</italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 272 277 272 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 344 346 344 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 357 359 357 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5</sup>
###xml 420 422 420 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 480 487 480 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDKN1A </italic>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdkn1a</italic>
###xml 312 317 <span type="species:ncbi:9606">human</span>
###xml 400 404 <span type="species:ncbi:10090">mice</span>
Using the MYC/Myc-driven cell transformation models, we next examined the differential expression of known KLF6 transcriptional targets of relevance to epithelial cancers, E-cadherin (CDH1 gene) [37] and p21 (CDKN1A) [38]. This analysis revealed strong down-regulation of CDH1 in the transformation of quiescent human mammary epithelial cells (P values < 10-5) and a trend in the model of Myc-driven mice tumorigenesis (P = 0.088). No significant differences were appreciable for CDKN1A or Cdkn1a. These observations suggest that KLF6 down-regulation mediated by germline MYC overexpression could promote epithelial neoplasia by down-regulating E-cadherin.
###end p 34
###begin title 35
Discussion
###end title 35
###begin p 36
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 810 814 810 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RAS </italic>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 836 841 836 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mad2 </italic>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 849 855 849 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 763 767 <span type="species:ncbi:10090">mice</span>
Combined analysis of genetic and expression data facilitates the identification of transcriptional regulators acting in any part of the genome [39,40]. Examination of different ethnic groups reinforces the identification of these regulators but also reveals differences between populations [41,42]. Due to their functional and structural complexity, transcriptional regulators are largely undercharacterized. However, it is thought that their genetic variability may be relevant when considering susceptibility to common diseases. Specifically, their causal relationship to cancer is almost unknown since most genetic analyses have been focused on coding regions. Insights into differential germline gene expression and tumorigenesis have been gained mainly from mice models, such as the overexpression of the RAS family of genes [43], Mad2 [44] or c-MYC [45,46].
###end p 36
###begin p 37
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 558 564 558 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
This study analyzed the hypothesis that variation at 8q24 cis-regulator(s) of transcription could significantly alter germline c-MYC expression levels and, thus, contribute to cancer susceptibility. Although the genetic scanning analysis performed is susceptible to false positives, the existence of true cis-regulator(s) is suggested by the identification of clusters of significant SNPs. Although larger sample series are required to draw definitive conclusions, the quantitative analysis of geneexpression in normal prostate tissues supports the model of c-MYC overexpression associated with Region 1 of prostate cancer risk. Tissue-specific cis-regulator(s) that correlate with additional cancer risk regions at 8q24 may also exist. In a recent study it was noted that tissue specificity is a critical factor in the transcriptional responsiveness of MYC targets [47].
###end p 37
###begin p 38
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 232 244 232 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC/c-Myc </italic>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 395 401 395 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 478 480 478 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 731 737 731 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 905 910 905 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 1167 1169 1167 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1170 1172 1170 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 341 346 <span type="species:ncbi:9606">human</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
The 8q24 region appears amplified in up to 50% of prostate tumors and c-MYC is thought to be the primary target of these amplifications since it is overexpressed in prostate hyperplasia and neoplasia [25]. Ectopic overexpression of c-MYC/c-Myc is sufficient to immortalize human prostate epithelial cells [17] and has been shown to generate human-like prostate tumors in mice [16]. In addition, c-MYC overexpression in prostate cancer cells enables androgen-independent growth [48]. These observations lead to suggestions of a dual role for c-MYC in prostate cancer. At early stages it would promote proliferation while at later stages it would facilitate androgen-independent growth [17]. Our study further proposes that germline c-MYC overexpression may promote cellular transformation of the normal epithelium and, by extension, risk of prostate cancer by down-regulating the prostate tumor suppressor KLF6 gene. This model is hypothetical and mainly based on the application of the ARACNe algorithm, which achieves a reasonable tradeoff between true- and false-positive rates by eliminating the majority of indirect interactions inferred from gene co-expression [49,50]. Experimental corroboration of the predictions generated in this study is therefore needed, particularly in prostate tissues or cell lines.
###end p 38
###begin p 39
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 592 597 592 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 756 761 756 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1 </italic>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 1250 1252 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1410 1415 1407 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC</italic>
###xml 1416 1418 1413 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1590 1595 1587 1592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC</italic>
###xml 1624 1629 1621 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 1671 1675 1668 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDH1</italic>
###xml 1698 1704 1695 1701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 796 801 <span type="species:ncbi:9606">human</span>
###xml 1524 1529 <span type="species:ncbi:9606">human</span>
The KLF6 gene is inactivated in prostate cancer by loss of heterozygosity and/or by somatic mutations identified in tumors, cell lines and xenografts [51]. Recent evidence has extended the role of KLF6 inactivation to several other neoplastic processes as esophageal carcinomas [52], glioblastomas [53], head and neck squamous cell carcinomas [54], hepatocellular carcinomas [55], non-small cell lung cancer [56], ovarian carcinomas [57] and particularly, with regard to 8q24 risk variants, to colorectal cancer [58]. A key KLF6 transcriptional target for epithelial neoplasia is E-cadherin (CDH1 gene), which is a suppressor of cellular invasion [37]. KLF6 directly transactivates the CDH1 promoter resulting in increased levels of its gene product [37]. CDH1 is genetically inactivated in many human cancers and shows reduced or absent expression in approximately 50% of prostate tumors [59], playing a critical role in the transition from a noninvasive to an invasive phenotype [60]. Notably, it has recently been proposed that EphB receptors act as tumor suppressors of colorectal cancer, and possibly breast and prostate cancer, through an E-cadherin-mediated mechanism that compartmentalizes tumor cells in the initial stages of tumorigenesis [61]. Loss of E-cadherin can result in beta-catenin nuclear localization and, as a result, the up-regulation of LEF/TCF-mediated transcriptional targets such as c-MYC[62]. Overall, our study suggests the existence of a transcriptional regulatory circuit that is perturbed in human cancer and which begins with the germline overexpression of c-MYC, causing down-regulation of KLF6 which then reduces the transactivation of CDH1, which in turns feeds c-MYC expression through beta-catenin and LEF/TCF transcriptional complex activation.
###end p 39
###begin p 40
###xml 91 92 91 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 628 636 628 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC/Myc </italic>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 891 897 891 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 947 951 947 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 1007 1009 1007 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 1085 1090 1085 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 1234 1236 1234 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 1237 1239 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 1387 1389 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1585 1591 1585 1591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 662 666 <span type="species:ncbi:10090">mice</span>
Variants at 8q24 have been associated with risk of prostate, breast and colorectal cancer [1-13,24,63]. Although there are different blocks of linkage disequilibrium that harbor risk variants, cancer clustering might suggests the existence of a common molecular mechanism of susceptibility. Expression analyses in normal prostate, breast and colorectal tissues and examination of association with genotypes are needed to determine the convergence on a common mechanism. Nonetheless, tumor tissue specificity may show dependences on specific, although not fully understood, mechanisms of neoplasia. The ectopic overexpression of MYC/Myc in specific cell types of mice promotes breast or prostate tumorigenesis [16,45,64], while widespread expression produces different types of tumors but with preferential appearance of specific epithelial and non-epithelial origins [46]. Overexpression of c-MYC also constitutes an early event after loss of the APC tumor suppressor gene that initiates colorectal cancer [62,65]. In addition, recent evidence shows that loss of heterozygosity at the KLF6 locus contributes to the transition from the compartmentalized carcinoma to the invasive carcinoma, specifically in sporadic colorectal cancer [66,67], which might suggest a link with the mechanism of tumor-cells compartmentalization in the initial stages of tumorigenesis mediated by E-cadherin [61]. Although the predictions generated in this study should be treated with a degree of caution, these observations would agree with the hypothesis of a cancer susceptibility mechanism mediated by c-MYC germlineoverexpression.
###end p 40
###begin title 41
Conclusion
###end title 41
###begin p 42
###xml 119 125 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6 </italic>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC</italic>
###xml 318 323 <span type="species:ncbi:9606">human</span>
This study proposes that variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline c-MYC expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor KLF6 gene. We propose a transcriptional regulatory model perturbed in human cancer with a feedback loop for c-MYC.
###end p 42
###begin title 43
Methods
###end title 43
###begin title 44
Genetic association analysis
###end title 44
###begin p 45
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 986 988 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 995 1002 995 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D'/LOD </italic>
###xml 1053 1055 1053 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
We analyzed HapMap genotypes and paired expression data recently made available for immortalized lymphocytes from four ethnic groups and including 210 independent individuals in total (60 Utah residents with ancestry from northern and western Europe; 45 Han Chinese in Beijing; 45 Japanese in Tokyo; and 60 Yoruba in Ibadan Nigeria; Gene Expression Omnibus (GEO) record GSE6536) [42]. Transcriptional differences were scanned between the 128 and 129 Mb of chromosome 8, corresponding to ~1,530 SNPs (NCBI build 35). Scans were performed in R with the SNPassoc package [68]. The log-additive effects of alleles were examined. Association of genotypes with the variable response (gene expression level) was calculated by fitting linear equations and P values obtained by assessing the change in deviance against the null model. Association analysis between genotypes, downloaded from the HapMap data release 21a, and gene expression levels were performed using the web-software SNPStats [69]. The D'/LOD plots were generated using the Haploview software [70].
###end p 45
###begin title 46
Microarray gene expression analysis
###end title 46
###begin p 47
###xml 45 47 45 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 444 450 444 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 454 458 454 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLF6</italic>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 731 733 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 875 876 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 882 884 882 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Using the HapMap lymphocyte expression data [42] and the prostate cancer data of Tomlins et al.[25], matrix series were downloaded from GEO references GSE6536 and GSE6099, respectively. Using the Singh et al.[30] raw data, background correction, normalization and averaging of expression values were performed with the robust multi-array average (RMA) algorithm. ARACNe Java [49,50] was used to model the gene expression regulatory networks of c-MYC and KLF6. In this analysis, data processing inequality (DPI) tolerance was set to 0.20 and the mutual information (MI) threshold was 0.05. Normalized data sets of MYC/Myc-driven cellular transformation and tumorigenesis were downloaded from the GEO records GSE3151 and GSE3158 [35,36]. Gene probes were matched using the NetAffx (Affymetrix) tool and differentially expressed probes were identified by calculating two-tailed t-test P values.
###end p 47
###begin title 48
Genotyping and quantitative RT-PCR analyses
###end title 48
###begin p 49
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 527 529 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 530 532 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 538 544 529 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
###xml 617 621 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 765 768 756 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">18S</italic>
###xml 770 776 761 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALAS1 </italic>
###xml 780 783 771 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 813 815 804 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R </italic>
###xml 817 818 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 818 819 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 820 824 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYC </italic>
###xml 818 824 809 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>c</italic>-<italic>MYC </italic></sub>
###xml 827 828 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 828 832 819 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 828 832 819 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>TBP </italic></sub>
###xml 834 835 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 835 839 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ALAS</italic>
###xml 835 840 826 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>ALAS</italic>1</sub>
###xml 848 849 839 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 849 856 840 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gene i </italic>
###xml 849 856 840 847 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>gene i </italic></sub>
###xml 858 860 849 851 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 860 867 851 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gene i </italic>
###xml 860 867 851 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>gene i </italic></sub>
###xml 869 871 860 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ct</italic>
###xml 874 875 865 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 871 875 862 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink">18 <italic>S</italic></sub>
Prostate tissue specimens were collected through the Tumor Bank of the Bellvitge University Hospital and the Catalan Institute of Oncology. Genotyping of rs1447295 was performed by direct sequencing of PCR products of genomic DNA using the following forward and reverse primers, respectively: 5'-GAGTTGCACGCCAGACACTA-3' and 5'-TTTCCCATACCCCATTCTGA-3'. Quantitative RT-PCR analysis of c-MYC was performed using a protocol previously developed with the LightCyclertrade mark DNA Master SYBR Green I Kit (Roche Applied Sciences) [20-22] and c-MYC primers 5'-CAGCTGCTTAGACGCTGGATT-3' and 5'-GTAGAAATACGGCTGCACCGA-3', and TBP primers 5'-GAACCACGGCACTGATTTTC-3' and 5'-CACAGCTCCCCACCATATTC-3'. Relative expression differences were calculated using three gene references (18S, ALAS1 and TBP) with the following formula: R = Fc-MYC - (FTBP - FALAS1) where Fgene i = Ctgene i - Ct18 S.
###end p 49
###begin title 50
Copy number variant analysis
###end title 50
###begin p 51
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
MLPA assays were performed following the conventional protocol with 150 ng of DNA, overnight ligation and 32 cycles of PCR. Probes for c-MYC were 5'-GGGTTCCCTAAGGGTTGGAGGAGGAACGAGCTAAAACGGAGCT-3' and 5'P-TTTTTGCCCTGCGTGACCAGATCCTCTAGATTGGATCTTGCTGGCAC-3'.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
XS participated in the study design, compiled and analyzed the HapMap data, performed the association analysis and the modeling of transcriptional regulatory networks. PH compiled and analyzed the prostate cancer expression data sets and performed the modeling of transcriptional regulatory networks. FA and EC obtained the tissue specimens. MLH, JA and VN performed the quantitative expression analysis. LA, BRS, LG, LPJ and XE performed the copy number variants analysis. CAM, GC and SBG participated in scientific discussions and helped with the overall interpretation of the data. XS, VM and MAP conceived and designed the study. MAP wrote the original and final versions of the manuscript. All authors read and approved the final version of the manuscript.
###end p 53
###begin title 54
Supplementary Material
###end title 54
###begin title 55
Additional file 1
###end title 55
###begin p 56
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC</italic>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-MYC </italic>
MLPA analysis of several cancer loci including c-MYC. Germline genomic gain at c-MYC was identified in a sample (bottom) by comparing relative peak intensities.
###end p 56
###begin p 57
Click here for file
###end p 57
###begin title 58
Acknowledgements
###end title 58
###begin p 59
The authors are indebted to all those who provided publicly available raw data used in this contribution. We thank Laura Gonzalez for technical assistance and to three anonymous reviewers for their helpful criticism. Tissue samples were collected through the Tumor Bank of the Bellvitge University Hospital and the Catalan Institute of Oncology, supported by the Tumor Bank Program and the RTICCC C03/10. This work was also supported by the Catalan Institute of Oncology, the "la Caixa" Foundation (BM05-254-00), the ISCIII (FIS-PI06/0545, RCESP-C03/09 and RTICCC-C03/10) and the Spanish Ministry of Education and Science (SAF-2003/5821 and SAF-2005/00166). CAM is supported by a Beatriu de Pinos fellowship from the Agencia de Gestio d'Ajuts Universitaris i de Recerca. MAP is a Ramon y Cajal Researcher with the Spanish Ministry of Education and Science.
###end p 59
###begin article-title 60
###xml 86 89 <span type="species:ncbi:9606">men</span>
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men
###end article-title 60
###begin article-title 61
A common variant associated with prostate cancer in European and African populations
###end article-title 61
###begin article-title 62
Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24
###end article-title 62
###begin article-title 63
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer
###end article-title 63
###begin article-title 64
A common 8q24 variant in prostate and breast cancer from a large nested case-control study
###end article-title 64
###begin article-title 65
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24
###end article-title 65
###begin article-title 66
Multiple regions within 8q24 independently affect risk for prostate cancer
###end article-title 66
###begin article-title 67
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
###end article-title 67
###begin article-title 68
Genome-wide association study identifies novel breast cancer susceptibility loci
###end article-title 68
###begin article-title 69
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21
###end article-title 69
###begin article-title 70
Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24
###end article-title 70
###begin article-title 71
A common genetic risk factor for colorectal and prostate cancer
###end article-title 71
###begin article-title 72
Genetic Variation in 8q24 Associated with Risk of Colorectal Cancer
###end article-title 72
###begin article-title 73
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma
###end article-title 73
###begin article-title 74
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype
###end article-title 74
###begin article-title 75
###xml 11 17 <span type="species:ncbi:10090">murine</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
Myc-driven murine prostate cancer shares molecular features with human prostate tumors
###end article-title 75
###begin article-title 76
###xml 27 32 <span type="species:ncbi:9606">human</span>
Immortalization of primary human prostate epithelial cells by c-Myc
###end article-title 76
###begin article-title 77
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Identification of somatic and germline mitochondrial DNA sequence variants in prostate cancer patients
###end article-title 77
###begin article-title 78
Aneuploidy of chromosome Y in prostate tumors and seminal vesicles: A possible sign of aging rather than an indicator of carcinogenesis?
###end article-title 78
###begin article-title 79
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
###end article-title 79
###begin article-title 80
Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer
###end article-title 80
###begin article-title 81
Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?
###end article-title 81
###begin article-title 82
###xml 65 70 <span type="species:ncbi:9606">human</span>
A comprehensive analysis of common copy-number variations in the human genome
###end article-title 82
###begin article-title 83
The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study
###end article-title 83
###begin article-title 84
Integrative molecular concept modeling of prostate cancer progression
###end article-title 84
###begin article-title 85
###xml 61 66 <span type="species:ncbi:9606">human</span>
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers
###end article-title 85
###begin article-title 86
###xml 41 46 <span type="species:ncbi:9606">human</span>
Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia
###end article-title 86
###begin article-title 87
###xml 12 17 <span type="species:ncbi:9606">human</span>
A census of human cancer genes
###end article-title 87
###begin article-title 88
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets
###end article-title 88
###begin article-title 89
Gene expression correlates of clinical prostate cancer behavior
###end article-title 89
###begin article-title 90
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of new human c-myc mRNA species produced by alternative splicing
###end article-title 90
###begin article-title 91
###xml 46 51 <span type="species:ncbi:9606">human</span>
Reverse engineering of regulatory networks in human B cells
###end article-title 91
###begin article-title 92
TRANSFAC: transcriptional regulation, from patterns to profiles
###end article-title 92
###begin article-title 93
Gene expression profiling predicts clinical outcome of prostate cancer
###end article-title 93
###begin article-title 94
###xml 32 37 <span type="species:ncbi:9606">human</span>
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
###end article-title 94
###begin article-title 95
Gene expression phenotypic models that predict the activity of oncogenic pathways
###end article-title 95
###begin article-title 96
E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor
###end article-title 96
###begin article-title 97
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 96 101 <span type="species:ncbi:9606">human</span>
In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma
###end article-title 97
###begin article-title 98
The genetics of variation in gene expression
###end article-title 98
###begin article-title 99
###xml 47 53 <span type="species:ncbi:9606">humans</span>
Allele-specific gene expression differences in humans
###end article-title 99
###begin article-title 100
Common genetic variants account for differences in gene expression among ethnic groups
###end article-title 100
###begin article-title 101
Relative impact of nucleotide and copy number variation on gene expression phenotypes
###end article-title 101
###begin article-title 102
###xml 115 130 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression of the N-ras proto-oncogene, not somatic mutational activation, associated with malignant tumors in transgenic mice
###end article-title 102
###begin article-title 103
###xml 61 65 <span type="species:ncbi:10090">mice</span>
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice
###end article-title 103
###begin article-title 104
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
###end article-title 104
###begin article-title 105
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development
###end article-title 105
###begin article-title 106
Integration of genome and chromatin structure with gene expression profiles to predict c-MYC recognition site binding and function
###end article-title 106
###begin article-title 107
Myc confers androgen-independent prostate cancer cell growth
###end article-title 107
###begin article-title 108
ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context
###end article-title 108
###begin article-title 109
Reverse engineering cellular networks
###end article-title 109
###begin article-title 110
KLF6, a candidate tumor suppressor gene mutated in prostate cancer
###end article-title 110
###begin article-title 111
Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma
###end article-title 111
###begin article-title 112
KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas
###end article-title 112
###begin article-title 113
KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma
###end article-title 113
###begin article-title 114
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma
###end article-title 114
###begin article-title 115
Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells
###end article-title 115
###begin article-title 116
Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination
###end article-title 116
###begin article-title 117
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer
###end article-title 117
###begin article-title 118
###xml 86 93 <span type="species:ncbi:9606">patient</span>
Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival
###end article-title 118
###begin article-title 119
Molecular biology of prostate cancer progression
###end article-title 119
###begin article-title 120
EphB-ephrin-B interactions suppress colorectal cancer progression by compartmentalizing tumor cells
###end article-title 120
###begin article-title 121
Identification of c-MYC as a target of the APC pathway
###end article-title 121
###begin article-title 122
Multiple prostate cancer risk variants on 8q24
###end article-title 122
###begin article-title 123
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
###end article-title 123
###begin article-title 124
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells
###end article-title 124
###begin article-title 125
Involvement of Kruppel-like factor 6 (KLF6) mutation in the development of nonpolypoid colorectal carcinoma
###end article-title 125
###begin article-title 126
###xml 198 206 <span type="species:ncbi:9606">patients</span>
Difference in the role of loss of heterozygosity at 10p15 (KLF6 locus) in colorectal carcinogenesis between sporadic and familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer patients
###end article-title 126
###begin article-title 127
SNPassoc: an R package to perform whole genome association studies
###end article-title 127
###begin article-title 128
SNPStats: a web tool for the analysis of association studies
###end article-title 128
###begin article-title 129
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 129

